STOCK TITAN

INOVIO Reports Inducement Grant Under Inducement Plan

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Very Positive)
Tags

INOVIO (NASDAQ:INO) announced an equity grant under its 2022 Inducement Plan for a newly hired employee. The Compensation Committee approved a stock option award of 1,666 shares with a grant date of November 30, 2024. The option has an exercise price of $4.32, based on the closing price on November 29, 2024. The stock option will vest in four equal installments: one-fourth on the grant date and additional one-fourth portions on the first, second, and third anniversaries, subject to continued employment.

INOVIO (NASDAQ:INO) ha annunciato una concessione di azioni nell'ambito del suo Piano di Induzione 2022 per un nuovo dipendente assunto. Il Comitato di Compensazione ha approvato un premio in opzioni azionarie di 1.666 azioni con una data di concessione del 30 novembre 2024. L'opzione ha un prezzo di esercizio di 4,32 dollari, basato sul prezzo di chiusura del 29 novembre 2024. L'opzione azionaria si maturerà in quattro rate uguali: un quarto alla data di concessione e porzioni aggiuntive di un quarto nei primi, secondi e terzi anniversari, soggette a continuazione del rapporto di lavoro.

INOVIO (NASDAQ:INO) anunció una concesión de acciones bajo su Plan de Inducción 2022 para un nuevo empleado contratado. El Comité de Compensación aprobó un premio de opción sobre acciones de 1,666 acciones con una fecha de concesión del 30 de noviembre de 2024. La opción tiene un precio de ejercicio de $4.32, basado en el precio de cierre del 29 de noviembre de 2024. La opción sobre acciones se concederá en cuatro partes iguales: una cuarta parte en la fecha de concesión y porciones adicionales de una cuarta parte en los primeros, segundos y terceros aniversarios, sujeto a la continuación del empleo.

INOVIO (NASDAQ:INO)는 새로 채용된 직원에게 2022 유도 계획에 따라 주식을 수여한다고 발표했습니다. 보상위원회는 2024년 11월 30일부여일에 1,666주의 스톡 옵션 상여를 승인했습니다. 이 옵션의 행사가는 $4.32로, 2024년 11월 29일의 종가를 기준으로 합니다. 스톡 옵션은 네 번에 걸쳐 동일한 분할로 만기됩니다: 부여일에 1/4가 만기되며, 첫 번째, 두 번째 및 세 번째 기념일에 추가적인 1/4씩 만기됩니다. 이는 재직 중임을 조건으로 합니다.

INOVIO (NASDAQ:INO) a annoncé une attribution d'actions dans le cadre de son Plan d'Induction 2022 pour un nouvel employé. Le Comité de Rémunération a approuvé une attribution d'options sur actions de 1 666 actions avec une date d'attribution fixée au 30 novembre 2024. L'option a un prix d'exercice de 4,32 $, basé sur le prix de clôture du 29 novembre 2024. L'option sera acquise en quatre versements égaux : un quart à la date d'attribution et des portions supplémentaires d'un quart aux première, deuxième et troisième anniversaires, sous réserve de la continuation de l'emploi.

INOVIO (NASDAQ:INO) gab eine Aktiengewährung im Rahmen seines Induktionsplans 2022 für einen neu eingestellten Mitarbeiter bekannt. Der Vergütungsausschuss genehmigte einen Aktienoptionszuschuss von 1.666 Aktien mit einem Zugangsdatum vom 30. November 2024. Der Ausübungspreis der Option beträgt 4,32 $, basierend auf dem Schlusskurs am 29. November 2024. Die Aktienoption wird in vier gleichen Raten fällig: ein Viertel am Zugangsdatum und weitere ein Viertel zu den ersten, zweiten und dritten Jahrestagen, vorbehaltlich der fortgesetzten Beschäftigung.

Positive
  • None.
Negative
  • None.

PLYMOUTH MEETING, Pa., Nov. 29, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan").

The Compensation Committee of INOVIO's Board of Directors has approved the award of an option to purchase 1,666 shares of common stock with a grant date of November 30, 2024 (the "Grant Date"), to a newly hired employee in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock option has an exercise price of $4.32, the closing price of INOVIO's common stock on November 29, 2024 (the last trading date preceding the Grant Date, which is not a trading day). The stock option will vest and become exercisable with respect to one-fourth of the shares underlying the stock option on the Grant Date, and an additional one-fourth of the shares underlying the stock option on the first, second, and third anniversaries of the Grant Date. The vesting of the stock option will be subject to the employee's continued employment with INOVIO on the applicable vesting dates. This award is subject to the terms and conditions of a stock option agreement under the Inducement Plan.

About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.

Contacts
Media: Jennie Willson, (267) 429-8567, jennie.willson@inovio.com
Investors: Thomas Hong, (267) 440-4298, thomas.hong@inovio.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-reports-inducement-grant-under-inducement-plan-302318984.html

SOURCE INOVIO Pharmaceuticals, Inc.

FAQ

What is the exercise price of INOVIO's (INO) new stock option grant announced on November 29, 2024?

The stock option has an exercise price of $4.32, which was INOVIO's closing price on November 29, 2024.

How many shares were granted in INOVIO's (INO) November 2024 inducement grant?

INOVIO granted stock options for 1,666 shares of common stock to a newly hired employee.

What is the vesting schedule for INOVIO's (INO) November 2024 inducement grant?

The stock option vests in four equal installments: one-fourth on the grant date and additional one-fourth portions on the first, second, and third anniversaries of the grant date.

Inovio Pharmaceuticals, Inc.

NASDAQ:INO

INO Rankings

INO Latest News

INO Stock Data

111.45M
25.88M
0.85%
33.51%
13.5%
Biotechnology
Surgical & Medical Instruments & Apparatus
Link
United States of America
SAN DIEGO